IntelGenx to Report First Quarter 2021 Financial Results on May 13, 2021 – Conference Call to Follow
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) will release its first quarter 2021 financial results on May 13, 2021, after market close. A conference call will follow at 4:30 p.m. ET, featuring CEO Dr. Horst G. Zerbe and CFO Andre Godin. The call will address financial results and provide a business update, and will be available live and archived on the company's website. IntelGenx specializes in drug delivery through innovative pharmaceutical films, highlighting advanced technologies such as VersaFilm® and VetaFilm™.
- Upcoming financial results announcement may provide insights into revenue performance.
- Conference call offers direct communication from leadership regarding business updates.
- None.
SAINT LAURENT, Quebec, May 06, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that it will release its first quarter 2021 financial results after market close on Thursday, May 13, 2021.
An accompanying conference call will be hosted by Dr. Horst G. Zerbe, Chief Executive Officer, and Mr. Andre Godin, President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:
| First Quarter 20210 Results Conference Call Details: | |
| Date: | Thursday, May 13, 2021 |
| Time: | 4:30 p.m. ET |
| Live Call: | 1-877-876-9176 (Canada and the United States) |
| 1-785-424-1670 (International) | |
The call will also be broadcast live and archived on the Company's website at www.intelgenx.com under "Webcasts" in the Investors section.
About IntelGenx
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.
IntelGenx’s superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.
IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.
Each of the TSX Venture Exchange and OTCQB has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.
For IntelGenx:
Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
stephen@intelgenx.com
Or
Andre Godin, CPA, CA
President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com
FAQ
When will IntelGenx release its first quarter 2021 financial results?
Who will be hosting the conference call for IntelGenx's financial results?
What time is the IntelGenx conference call on May 13, 2021?
Where can I listen to the IntelGenx conference call?
What is the focus of IntelGenx's business?
